Financing ·
Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026, to sell 12,962,963 American…
SLNSilence Therapeutics plc
Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026, to sell 12,962,963 American Depositary Shares (ADSs) in an underwritten public offering. Each ADS represents three ordinary shares and was priced at $13.50 per share. The company granted the underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs. Net proceeds are estimated at approximately $164.0 million, or $188.7 million if the over-allotment option is exercised in full, after deducting underwriting discounts and offering expenses. The closing of the offering is expected to occur on August 13, 2026. Jefferies LLC and Morgan Stanley & Co. LLC are acting as representatives for the underwriters. Silence Therapeutics plc operates in the biotechnology industry, developing short interfering RNA (siRNA) therapies.